Leerink Swann Weighs in on Aquinox Pharmaceuticals, Inc.’s FY2017 Earnings (AQXP)

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) – Investment analysts at Leerink Swann boosted their FY2017 EPS estimates for shares of Aquinox Pharmaceuticals in a research note issued on Wednesday. Leerink Swann analyst P. Matteis now forecasts that the company will earn ($2.09) per share for the year, up from their prior forecast of ($2.21). Leerink Swann also issued estimates for Aquinox Pharmaceuticals’ FY2018 earnings at ($2.50) EPS.

Several other analysts have also recently issued reports on the stock. BidaskClub cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. ValuEngine cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Needham & Company LLC reissued a “buy” rating and set a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $22.50.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://ledgergazette.com/2017/11/13/leerink-swann-weighs-in-on-aquinox-pharmaceuticals-inc-s-fy2017-earnings-aqxp.html.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at $10.88 on Monday. Aquinox Pharmaceuticals has a 12 month low of $10.68 and a 12 month high of $19.97.

Several large investors have recently bought and sold shares of AQXP. Nexthera Capital LP acquired a new position in shares of Aquinox Pharmaceuticals during the 2nd quarter valued at $1,276,000. Sphera Funds Management LTD. acquired a new position in shares of Aquinox Pharmaceuticals during the 2nd quarter valued at $874,000. Vanguard Group Inc. lifted its holdings in shares of Aquinox Pharmaceuticals by 6.6% during the 2nd quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after acquiring an additional 17,455 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Aquinox Pharmaceuticals during the 3rd quarter valued at $194,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Aquinox Pharmaceuticals by 10.0% during the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after acquiring an additional 11,035 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Earnings History and Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply